Vertex Raises 2026 Revenue Guidance Amid Portfolio Diversification
Vertex Pharmaceuticals (VRTX) has raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion following strong third-quarter performance. The company reported a 12% year-over-year increase in total revenue, driven significantly by the growth of JOURNAVX, which saw prescriptions rise 40% sequentially. The company is aggressively diversifying its revenue streams beyond its core cystic fibrosis business. Key strategic moves include expanding into rare endocrinology via the acquisition of Crinetics Pharmaceuticals and advancing a renal pipeline with povitacept for kidney disease. Management is prioritizing long-term market share in new categories, even if it requires short-term discounting through extended patient support programs.
Topics: biotechnology earnings report expansion strategy revenue guidance
Read the full article at Motley Fool
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)